


Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 14th day of August 2006.

(s)


Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Chen et al.	Atty. Docket:	PRD2045NP-US
Serial No.:	10/786,478	Art Unit:	1647
Filed:	February 25, 2004	Examiner:	Ian D. Dang
For:	Relaxin3-GPCR135 Complexes And Their Production And Use	Confirmation No.:	1497

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statement filed in the above-identified application on September 14, 2004. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing additional references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(b)(3), i.e., before the mailing of a first Office Action on the merits. In the event that a first Office Action has been mailed, then this Statement is being filed under 37 C.F.R. § 1.97(c)(2) and the Commissioner is requested to charge Deposit Account No. 10-0750 for the \$180.00 fee set forth in 37 C.F.R. § 1.17(p).

A copy of each reference listed on the Form PTO-1449 is enclosed. Each reference is in the English language.

Applicant also notes that a counterpart U.S. patent application, Serial No. 10/547,875, which is a national phase of International Application No. PCT/US2004/005666 filed February 25, 2004, is copending.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of the references.

If any fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.


Respectfully submitted,

Date: August 14, 2006



Linda S. Evans
Reg. No. 33,873

LSE/MDR
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PRD2045NP-USSERIAL NO.
10/786,478**INFORMATION DISCLOSURE
CITATION BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Chen et al.FILING DATE
February 25, 2004GROUP ART UNIT
1647**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
WO 200 6 0 2 6 3 5 5	March 9, 2006	WIPO			
WO 200 5 0 1 4 6 1 6	February 17, 2005	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chen et al., "Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species," <i>J. Pharmacol. Exp. Ther.</i> , Vol. 312(1), pp. 83-95 (2005).
	Liu et al., "Identification of relaxin-3/INSL7 as a ligand for GPCR142," <i>J. Biol. Chem.</i> , Vol. 278(50), pp. 50765-50770 (2003).
	Liu et al., "Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135," <i>J. Biol. Chem.</i> , Vol. 278(50), pp. 50754-50764 (2003).
	Liu et al., "INSL5 is a high affinity specific agonist for GPCR142 (GPR100)," <i>J. Biol. Chem.</i> , Vol. 280(1), pp. 292-300 (2005).
	Liu et al., "Recent progress in relaxin-3-related research," <i>Ann. NY Acad. Sci.</i> , Vol. 1041, pp. 47-60 (2005).
	Liu et al., "Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7," <i>Mol. Pharmacol.</i> , Vol. 67(1), pp. 231-240 (2005).
	Sutton et al., "Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing," <i>Neuroendocrinology</i> , Vol. 80(5), pp. 298-307 (2005).
	Sutton et al., "G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: further support that relaxin-3 is the physiological ligand for GPCR135," <i>Neuroendocrinology</i> , Vol. 82, pp. 139-150 (2005).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.